Breast MRI showdown: which contrast agent is better?
NCT ID NCT03730051
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study compared two MRI contrast agents, Dotarem and Gadavist, in 300 women undergoing breast MRI. The goal was to see if Dotarem is as effective as Gadavist at enhancing breast lesions for clearer images. Participants were randomly assigned to receive one of the two agents, and radiologists graded the image quality. The results could help doctors choose the best contrast agent for breast cancer detection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gadoterate meglumine (Dotarem) and gadobutrol (Gadavist)
What this could lead to
If successful, this could show that Dotarem is as good as Gadavist for breast MRI, giving doctors more options for clear imaging.
What could go wrong
This is a completed Phase 4 study focused on image quality, not on curing or treating disease. The results may not change current practice significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UMass Medical School
Worcester, Massachusetts, 01655, United States